GlassScriptPhysician profile
Meaza Germame
NPI 1750939484
$1,667.09
in general payments reported to CMS, 2019-2025
12 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $402 · 2022: $79.67 · 2023: $332 · 2024: $377 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,185.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $361.81 | 2023-2024 | Lybalvi, Aristada, Aristada Initio |
| Neurocrine Biosciences, INC. | $250.79 | 2025 | |
| Janssen Pharmaceuticals, INC | $222.23 | 2023-2024 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $211.22 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $191.60 | 2021-2022 | |
| Novo Nordisk INC | $141.47 | 2021 | |
| Vanda Pharmaceuticals INC. | $139.75 | 2024-2025 | Fanapt |
| Lilly USA, LLC | $74.95 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.51 | 2021 | |
| Glaxosmithkline, LLC. | $17.11 | 2021 | |
| Amarin Pharma, INC. | $17.00 | 2021 | |
| Hologic Sales and Service, LLC | $16.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meaza Germame listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.